News

Two distinguished Weill Cornell Medicine physician-scientists have been elected to the prestigious Association of American Physicians (AAP). 

Awards, honors, prizes and achievements for the month of June.

An understudied type of liver cell may drive scarring in liver disease and could be a promising target for new treatments, suggests a new study by Weill Cornell Medicine investigators.

An enzyme has been discovered to play a critical role in blocking the metabolic processes that contribute to the rapid growth and spread of liver cancer, according to a new study by Weill Cornell Medicine researchers.

The hormonal shifts that occur with menopause can increase the risk of brain changes associated with Alzheimer’s disease, according to new research from Weill Cornell Medicine investigators.

With COVID-19 limiting resources and presenting logistical challenges for elective treatments, Weill Cornell Medicine and NewYork-Presbyterian clinicians offer guidance on treating cancer in three recently published papers.

When COVID-19 first appeared in NYC hospitals, Weill Cornell Medicine and NewYork-Presbyterian physicians and scientists documented early observations of clinical and pathological characteristics in two publications.

A new technique that involves growing brain tumors in a miniature laboratory model of the human brain recreated the complex genetics of the disease better than other approaches, according to research by investigators at Weill Cornell Medicine and NewYork-Presbyterian.

As the epicenter of the COVID-19 pandemic moves to Latin America and Africa, Weill Cornell Medicine faculty based in Haiti, a country hard hit by natural disasters and poverty, have developed lessons on what low-resourced countries can do to address and treat the outbreak on the ground.

The benefits of the prostate-specific antigen (PSA) test to screen men for prostate cancer may be greater than the harm, say investigators at Weill Cornell Medicine, NewYork-Presbyterian, University of Washington School of Medicine and the Fred Hutchinson Cancer Research Center.

Dr. Kevin Holcomb, a prominent gynecologic oncologist with a longstanding commitment to medical education and leadership, has been named associate dean for admissions at Weill Cornell Medical College, effective July 1. Dr. Jessica Peña, an expert in cardiology and a dedicated mentor of students, residents and fellows, has been appointed to the newly created position of assistant dean for admissions.

Epidemiological models of COVID-19 that are used to guide policies on social distancing measures should take into account the special dynamics of the coronavirus’s spread in nursing homes and other long-term care (LTC) facilities.

Critical care physicians, infectious disease specialists and pulmonologists from Weill Cornell Medicine and NewYork-Presbyterian have published a clinical practice guide for managing severe COVID-19 in the New England Journal of Medicine.

Dr. Jim Hu, the Ronald P. Lynch Professor of Urologic Oncology at Weill Cornell Medicine, has been awarded more than $7 million in funding from the Patient-Centered Outcomes Research Institute (PCORI) for two studies on outcomes of prostate cancer biopsy and treatment.

Three proteins bind to chemical marks on molecular messages in cells, targeting the messages for degradation, according to researchers at Weill Cornell Medicine. The results overturn some prevailing models of how cells use chemical tags to control their genes' expression and may offer new targets for treating leukemia, which can arise when the chemical tags go awry.

An intensive, one-year, lifestyle-modification treatment for type 2 diabetes patients, featuring a low-calorie diet and physical exercise, resulted in a large average weight loss, and remission of diabetes for most patients, in a clinical trial led by researchers at Weill Cornell Medicine-Qatar.

In randomized clinical trials, commercial sponsorship influences how studies are designed and the results reported in ways that often benefit the study’s sponsor, Weill Cornell Medicine and NewYork-Presbyterian investigators report.

A DNA-sequencing strategy powered by machine learning may pick up even very low levels of tumor DNA in blood samples, potentially enabling the early detection of cancer recurrence after surgery or other treatments, according to a study led by scientists at Weill Cornell Medicine and the New York Genome Center (NYGC).

Awards, honors, prizes and achievements for the month of May.

Like more than half of Weill Cornell Medicine’s Class of 2020, Dr. Kevin Ackerman chose to graduate early to be of service to New York City’s healthcare system during the COVID-19 pandemic.